Credit: Ludwig Cancer Research
APRIL 28, 2021, NEW YORK - A Ludwig Cancer Research study has identified a previously unrecognized mechanism by which cancer cells of a relatively benign subtype of pancreatic tumors methodically revert or de-differentiate to a progenitor, or immature, state of cellular development to spawn highly aggressive tumors that are capable of metastasis to the liver and lymph nodes.
The study, led by Ludwig Lausanne s Douglas Hanahan and published in
Cancer Discovery, a journal of the American Association for Cancer Research, also shows that engagement of the mechanism is associated with poorer outcomes in patients diagnosed with pancreatic neuroendocrine tumors (PanNETs). Further, its findings provide concrete evidence that such cellular de-differentiation, widely observed across cancer types, is a not merely a random consequence of cancer cells other aberrations.
Date Time
Ludwig Cancer Research study shows pancreatic cancer cells hit reverse to advance in malignancy
APRIL 28, 2021, NEW YORK – A Ludwig Cancer Research study has identified a previously unrecognized mechanism by which cancer cells of a relatively benign subtype of pancreatic tumors methodically revert-or “de-differentiate”-to a progenitor, or immature, state of cellular development to spawn highly aggressive tumors that are capable of metastasis to the liver and lymph nodes.
The study, led by Ludwig Lausanne’s Douglas Hanahan and published in Cancer Discovery, a journal of the American Association for Cancer Research, also shows that engagement of the mechanism is associated with poorer outcomes in patients diagnosed with pancreatic neuroendocrine tumors (PanNETs). Further, its findings provide concrete evidence that such cellular de-differentiation, widely observed across cancer types, is a not merely a random consequence of cancer cells’ other aberrations.